ASX Biotech/Company Directory

/

descriptionAnnouncements scienceTrials warningRisk Matrix bookmarkWatchlist feedbackFeedback settingsSettings

IMMImmutep Limited

data caveat$109M—

Companies/IMM

IMMActiveTier 2

Immutep Limited

Biotechnology · Oncology

Clinical-stage biotech developing LAG-3-based immunotherapies for cancer and autoimmune disease; lead asset eftilagimod alpha is in Phase 2/3 for breast cancer and HNSCC.

Website ↗ASX ↗

Data HealthTrials5 of 6 active · stale enrollment

No cash data on fileFigures from ASX filings · not financial advice

[ VITALS ]

Cash on Hand

—

Runway

—

Market Cap

$109M

Burn Rate

—

Shares Outstanding

1.5B

Pipeline Assets

IMM

Latest Insight(1)

16 Apr 2026

substantial_holderChange in substantial holding

Changed·JPMorgan Chase & Co. and its affiliates·5.43%

picture_as_pdfView full announcement

3M Price

IMM.ASX

$0.074-82.2% 3M

Low $0.036High $0.460

Pipeline Assets (8)

IMP761autoimmune diseases

Phase 1

IMP761autoimmune diseases

Phase 1

Eftilagimod alpha (efti)soft tissue sarcoma

Phase 2

eftilagimod alpha (efti)soft tissue sarcoma

Phase 2

eftilagimod alpha (efti)head and neck squamous cell carcinoma

Phase 2

Eftilagimod alpha (efti)head and neck squamous cell carcinoma

Phase 2

Capital Raises & Buybacks

show_chart

No capital raise or buyback data

Substantial Holders (5%+ threshold)

10 notices

arrow_drop_downJPMorgan Chase & Co. and its affiliates

6.94%→5.43%80,085,921 sh2026-04-16

arrow_drop_downJPMorgan Chase & Co. and its affiliates

8.28%→6.94%102,267,865 sh2026-04-10

Director Options & Rights

Director

Outstanding

Ex. Price

Expiry

No option data entered yet

Short Interest

ASIC ↗as of 2026-03-27 · 4-day lag

Short position

0.55%

arrow_drop_up+0.00% over 2 reports

Shares short

8.1M

Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data

Competitive Landscape

5 approved drugs1000 competitor trialsPhase 2+ · Non-ASX

Autoimmune Diseases248 active trials

108 Ph2140 Ph1/PHASE2

Soft Tissue Sarcoma195 active trials

93 Ph2102 Ph1/PHASE2

Approved

Doxorubicin Hydrochloride

Head And Neck Squamous Cell Carcinoma287 active trials

172 Ph2115 Ph1/PHASE2

Approved

KEYTRUDA KEYTRUDA QLEX

Metastatic Breast Cancer270 active trials

122 Ph2148 Ph1/PHASE2

Approved

Docetaxel Doxorubicin Hydrochloride

Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.

expand_more

Clinical Publications

Peer-reviewed papers & conference abstracts via PubMed

2 papers

LAG-3 in (auto)immunity and cancer - Emphasising its role in antigen presenting cells.

Autoimmun Rev2026-02· Eftilagimod alphaReview

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

Future Oncol2025-12· eftiClinical Trial Protocol

Catalysts (15)· 9 upcoming · 6 past

IMP761 Phase I data at EULAR 2026

Upcoming

Confirmedarrow_upwardHigh4 June 2026

IMP761 Phase I data at EULAR 2026

Upcoming

Confirmedarrow_upwardHigh4 June 2026

IMP761 Phase I MAD portion completionopen_in_new

Upcoming

Expectedarrow_upwardHigh30 Sept 2026

IMP761 Phase I MAD completion

Delivery Consistency Index

Historical delivery and spending consistency — data is limited for recently added companies.

Delivery Consistency Index

Delivery

–Insufficient data

0/3 data points needed

Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts

Capital discipline

–Insufficient data

0/2 data points needed

Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus

Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.

These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.

⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED

These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.

★ RESULTS

NCT01308294 ↗Results posted to ClinicalTrials.gov

2026-04-13

★ RESULTS

NCT03625323 ↗Results posted to ClinicalTrials.gov

2026-04-13

★ RESULTS

NCT01308294 ↗Results posted to ClinicalTrials.gov

2026-04-08

★ RESULTS

NCT03625323 ↗Results posted to ClinicalTrials.gov

2026-04-08

Clinical Trials(8)

6 activeClinicalTrials.gov ↗

Ph1RecruitingEnrollment stale · 644d

IMP761Placebokeyhole limpet haemocyanin (KLH)

A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers

Healthy

RandomizedDouble Blind18 Years – 55 Years

Primary endpoint Occurrence of clinically relevant abnormalities in vital signs

NCT06637865 ↗CT.gov

Start

2024-07

Primary end

2026-04

Ph2Not Yet Recruiting

Eftilagimod Alfa (Efti)Docetaxel-cyclophosphamide (TC) intravenous (i.v)Dose dense Adriamycin-cyclophosphamide (AC) i.v

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Breast Cancer · HER 2 Negative Breast Cancer · HR Positive/HER-2 Negative Breast Cancer +1 more

21 Years+

Primary endpoint To determine pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and Efti treatment

NCT07102940 ↗CT.gov

Start

2026-05

Primary end

2028-08

Ph1Active Not RecruitingEnrollment stale · 3172d

IMP321Avelumab

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Solid Tumors · Peritoneal Carcinomatosis · NSCLC Adenocarcinoma +1 more

18 Years+

Primary endpoint Feasibility rate

NCT03252938 ↗CT.gov

Start

2017-08

Primary end

2026-09

Announcements(11)

All announcements →

description

Presentation

Abstract on Efti accepted for presentation at ASCO 2026

22 Apr 2026

130KB

article

substantial_holderauto_awesome

Change in substantial holding

16 Apr 2026

1043KB

expand_more

verified

RegulatoryPSauto_awesome

Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma

14 Apr 2026

175KB

expand_more

article

substantial_holderauto_awesome

Change in substantial holding

12 Apr 2026

695KB

expand_more

article

substantial_holderauto_awesome

Change in substantial holding

9 Apr 2026

1131KB

expand_more

Event	Type	Confidence	Impact	Date	Status
IMP761 Phase I data at EULAR 2026 SAD Phase I results for LAG-3 agonist IMP761 to be presented at EULAR Congress, London; dose-dependent T cell suppression demonstrated	conference presentation	Confirmed	arrow_upwardHigh	4 June 2026	Upcoming
IMP761 Phase I data at EULAR 2026 SAD/MAD data for first-in-class LAG-3 agonist in autoimmune disease	conference presentation	Confirmed	arrow_upwardHigh	4 June 2026	Upcoming
IMP761 Phase I MAD portion completionopen_in_new The multiple ascending dose (MAD) portion of the Phase I study is currently ongoing across two dose levels, with completion expected in Q3 2026. [Source: Update on Phase I Study of IMP761 for Autoimmune Diseases, 2026-03-18]	data readout	Expected	arrow_upwardHigh	30 Sept 2026	Upcoming
IMP761 Phase I MAD completion Multiple ascending dose cohorts ongoing; no safety issues to date; completion guides Phase II dose selection	data readout	Expected	arrow_upwardHigh	30 Sept 2026	Upcoming
TACTI-003 HNSCC registrational path decision FDA feedback on registrational or single-arm trial pathway for CPS<1 HNSCC	regulatory decision	Speculative	arrow_upwardHigh	31 Dec 2026	Upcoming
AIPAC-003 Phase 3 breast cancer update Interim or enrollment update for Phase 3 efti in metastatic breast cancer	data readout	Speculative	arrow_upwardHigh	31 Dec 2026	Upcoming
AIPAC-003 Phase III breast cancer update Phase III arm of AIPAC-003 progressing following Phase II enrolment completion Oct 2024; full readout timing not yet publicly guided	data readout	Speculative	arrow_upwardHigh	31 Dec 2026	Upcoming
PHASE3 data readout — Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotheropen_in_new Primary completion expected for NCT06726265. Indication: {"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)"}	data readout	Speculative	removeMed	1 June 2027	Upcoming
PHASE2 data readout — Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Canceropen_in_new Primary completion expected for NCT07102940. Indication: {"Breast Cancer","HER 2 Negative Breast Cancer","HR Positive/HER-2 Negative Breast Cancer","Stage 1-3"}	data readout	Speculative	removeMed	1 Aug 2028	Upcoming

expand_more6 past catalysts

Update on Phase I Study of IMP761 for Autoimmune Diseasesopen_in_new The single ascending dose (SAD) portion of the first-in-human Phase I study has been successfully completed, with dosing up to 14 mg/kg in healthy participants. IMP761 demonstrated a clear immunosuppressive effect, showing durable inhibition of T-cell-mediated responses after a single administration in participants challenged with a foreign antigen. The multiple ascending dose (MAD) portion is currently ongoing across two dose levels, with completion expected in Q3 2026.	data readout	Confirmed	removeMed	18 Mar 2026	Completed
Results posted — Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) aopen_in_new Results available at https://clinicaltrials.gov/study/NCT03625323	data readout	Confirmed	High

Immutep Limited

Latest Insight(1)

3M Price

Pipeline Assets (8)

Capital Raises & Buybacks

Substantial Holders (5%+ threshold)

Director Options & Rights

Short Interest

Competitive Landscape

Clinical Publications

Catalysts (15)· 9 upcoming · 6 past

Delivery Consistency Index

Clinical Trials(8)

Announcements(11)

Quarterly Cash Flow